|
Hemato-oncology
Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy
In Hee Lee, Byung Woog Kang, Jong Gwang Kim, Woo Kyun Bae, Myung Seo Ki, Inkeun Park, Jae-Cheol Jo, Jin Young Kim, Sung Ae Koh, Kyung Hee Lee, Yoon Young Cho, Hun Mo Ryoo, Sang Gyu Kwak, Jung Lim Lee, Sun Ah Lee
Korean J Intern Med. 2020;35(1):185-193. Published online October 12, 2018
Background/Aims: For metastatic renal cell carcinoma (RCC), various prognostic scoring systems have been developed. However, owing to the low prevalence of nonclear cell RCC, the three most commonly used tools were mainly developed based on patients with clear cell histology. Accordingly, this study..
|
|
|
No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
Sang Kyun Sohn, Joon Ho Moon, In Hee Lee, Jae Sook Ahn, Hyeoung Joon Kim, Joo Seop Chung, Ho Jin Shin, Sung Woo Park, Won Sik Lee, Sang Min Lee, Hawk Kim, Ho Sup Lee, Yang Soo Kim, Yoon Young Cho, Sung Hwa Bae, Ji Hyun Lee, Sung Hyun Kim, Ik Chan Song, Ji Hyun Kwon, Yoo Jin Lee
Korean J Intern Med. 2018;33(6):1194-1202. Published online December 15, 2017
Background/Aims: This study evaluated the role of hypomethylating agents (HMA) compared to best supportive care (BSC) for patients with high or very-high (H/VH) risk myelodysplastic syndrome (MDS) according to the Revised International Prognostic Scoring System.
Methods: A total of 279 H/VH risk MD..
|
|
|
